Phase I study of nivolumab or nivolumab/cisplatin/gemcitabine to treat unresectable/recurrent biliary tract cancer

被引：0
|
作者：
Morizane, Chigusa [1 ]
Ikeda, Masafumi [2 ]
Ueno, Makoto [3 ]
Kobayashi, Satoshi [3 ]
Ohno, Izumi [2 ]
Kondo, Shunsuke [1 ]
Okano, Naohiro [4 ]
Kimura, Keisuke [5 ]
Asada, Suguru [5 ]
Namba, Yoshinobu [5 ]
Okusaka, Takuji [1 ]
Furuse, Junji [4 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[4] Kyorin Univ, Fac Med, Mitaka, Tokyo, Japan
[5] Ono Pharmaceut Co Ltd, Osaka, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz339.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O2 - 2 - 4
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [41] A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).
    Kim, Richard D.
    Kim, Dae Won
    Alese, Olatunji B.
    Li, Daneng
    Shah, Neal
    Schell, Michael J.
    Zhou, Jun Min
    Chung, Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
    Valle, Juan
    Wasan, Harpreet
    Palmer, Daniel H.
    Cunningham, David
    Anthoney, Alan
    Maraveyas, Anthony
    Madhusudan, Srinivasan
    Iveson, Tim
    Hughes, Sharon
    Pereira, Stephen P.
    Roughton, Michael
    Bridgewater, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (14): : 1273 - 1281
  • [43] Phase I study of gemcitabine, cisplatin, and S-1 combination therapy for patients with untreated advanced biliary tract cancer
    Moriwaki, Toshikazu
    Ishida, Hiroyasu
    Araki, Masahiro
    Endo, Shinji
    Yoshida, Shigemasa
    Kobayashi, Mariko
    Hamano, Yukako
    Sugaya, Akinori
    Shimoyamada, Masahiro
    Hasegawa, Naoyuki
    Imanishi, Mamiko
    Ito, Yuka
    Sato, Daiki
    Hyodo, Ichinosuke
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2015, 22 (09) : 669 - 674
  • [44] Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer
    Mimura, Kosaku
    Ogata, Takashi
    Yoshimoto, Yuya
    Yoshida, Daisaku
    Nakajima, Shotaro
    Sato, Hisashi
    Machida, Nozomu
    Yamada, Takanobu
    Watanabe, Yohei
    Tamaki, Tomoaki
    Fujikawa, Hirohito
    Inokuchi, Yasuhiro
    Hayase, Suguru
    Hanayama, Hiroyuki
    Saze, Zenichiro
    Katoh, Hiroyuki
    Takahashi, Fumiaki
    Oshima, Takashi
    Suzuki, Yoshiyuki
    Kono, Koji
    COMMUNICATIONS MEDICINE, 2023, 3 (01):
  • [45] Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer
    Kosaku Mimura
    Takashi Ogata
    Yuya Yoshimoto
    Daisaku Yoshida
    Shotaro Nakajima
    Hisashi Sato
    Nozomu Machida
    Takanobu Yamada
    Yohei Watanabe
    Tomoaki Tamaki
    Hirohito Fujikawa
    Yasuhiro Inokuchi
    Suguru Hayase
    Hiroyuki Hanayama
    Zenichiro Saze
    Hiroyuki Katoh
    Fumiaki Takahashi
    Takashi Oshima
    Yoshiyuki Suzuki
    Koji Kono
    Communications Medicine, 3
  • [46] Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer.
    Chawla, Sant P.
    Chua, Victoria S.
    Gordon, Erlinda Maria
    Moradkhani, Ania
    Kim, Katherine
    Quon, Doris
    Wong, Steven
    Sumner, Robert
    Mac, Virginia
    Huang, Raymond
    Wang, Kelly
    Kim, Jiyeun
    Kim, Bumjin
    McGinn, Arlo N.
    Park, Cheol Hee
    Houston, Scott
    Sankar, Neil
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [47] Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE)
    Ueno, M.
    Morizane, C.
    Ikeda, M.
    Ozaka, M.
    Nagashima, F.
    Kataoka, T.
    Mizusawa, J.
    Ohba, A.
    Kobayashi, S.
    Imaoka, H.
    Kasuga, A.
    Okano, N.
    Nagasaka, Y.
    Kurishita, K.
    Tomatsuri, S.
    Sasaki, M.
    Shibata, T.
    Nakamura, K.
    Furuse, J.
    Okusaka, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S569 - S570
  • [48] Nivolumab monotherapy and associations in the treatment of advanced unresectable biliary tract cancer (BTC): A systematic review and meta-analysis
    Filogonio, Victor
    Maia, Yara Rafaela
    Maia, Lucas Henrique
    Beck, Mauren Carbonar
    Beck, Theodoro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Gemcitabine Plus Cisplatin Versus Gemcitabine Chemotherapy for Advanced Biliary Tract Cancer
    Park, Jin Myung
    Ryu, Ji Kon
    Paik, Woo Hyun
    Song, Byeong Jun
    Park, Joo Kyung
    Kim, Yong-Tae
    Yoon, Yong Bum
    GASTROENTEROLOGY, 2013, 144 (05) : S529 - S529
  • [50] Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
    Goyal, Lipika
    Sirard, Cynthia
    Schrag, Michael
    Kagey, Michael H.
    Eads, Jennifer R.
    Stein, Stacey
    El-Khoueiry, Anthony B.
    Manji, Gulam A.
    Abrams, Thomas A.
    Khorana, Alok A.
    Miksad, Rebecca
    Mahalingam, Devalingam
    Zhu, Andrew X.
    Duda, Dan G.
    CLINICAL CANCER RESEARCH, 2020, 26 (23) : 6158 - 6167
12345